Tags

Type your tag names separated by a space and hit enter

Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience.
Front Neurol. 2020; 11:105.FN

Abstract

Introduction: Trends of disease activity during pregnancy, the postpartum period, and until 24 months from the delivery in the era of new drugs for the treatment of relapsing-remitting multiple sclerosis (RRMS) need to be investigated.

Methods:

In this cross-sectional Italian multicenter study, women with RRMS were included; the disease-modifying treatment (DMT) at the time of conception included were: interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, fingolimod, and natalizumab. The main outcome of the study was to determine the rate of relapse occurrence during pregnancy and the postpartum period in all women grouped for each DMT. The secondary outcome was to determine the overall disease activity assessed by NEDA 3 (relapse, disability level, and radiological activity) at 24 months from the date of delivery.

Results:

Completed data were available for 81 pregnancies (in 74 women). Women on interferons and glatiramer had longer disease duration than women on dimethyl fumarate, fingolimod, and natalizumab (p < 0.05). Overall, we recorded 25 relapses during pregnancy (11 in 11 women) and the postpartum period (14 in 14 women). Natalizumab was the most commonly DMT in women (3) who experienced relapses during pregnancy. IFNs were the most commonly prescribed DMT in women (8) who experienced relapses during the postpartum period. At logistic regression analysis, specific treatment per se was not associated with relapse occurrence. No differences among the DMTs groups were recorded about NEDA 3 status at 24 months of follow-up.

Conclusions:

In our population, there was no difference in terms of relapses occurrence, disability status, and the overall disease activity during a follow up of 24 months.

Authors+Show Affiliations

Department "G. F. Ingrassia", University of Catania, Catania, Italy.Department "G. F. Ingrassia", University of Catania, Catania, Italy.Institute Foundation "G. Giglio", MS Center, Cefalù-Palermo, Italy.Department "G. F. Ingrassia", University of Catania, Catania, Italy.S. Andrea Hospital, Rome, Italy.Institute Foundation "G. Giglio", MS Center, Cefalù-Palermo, Italy.Department "G. F. Ingrassia", University of Catania, Catania, Italy.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32158424

Citation

Zanghì, Aurora, et al. "Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: a Real-World Multicenter Experience." Frontiers in Neurology, vol. 11, 2020, p. 105.
Zanghì A, D'Amico E, Callari G, et al. Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience. Front Neurol. 2020;11:105.
Zanghì, A., D'Amico, E., Callari, G., Chisari, C. G., Borriello, G., Grimaldi, L. M. E., & Patti, F. (2020). Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience. Frontiers in Neurology, 11, 105. https://doi.org/10.3389/fneur.2020.00105
Zanghì A, et al. Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: a Real-World Multicenter Experience. Front Neurol. 2020;11:105. PubMed PMID: 32158424.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience. AU - Zanghì,Aurora, AU - D'Amico,Emanuele, AU - Callari,Graziella, AU - Chisari,Clara Grazia, AU - Borriello,Giovanna, AU - Grimaldi,Luigi Maria Edoardo, AU - Patti,Francesco, Y1 - 2020/02/25/ PY - 2019/09/22/received PY - 2020/01/30/accepted PY - 2020/3/12/entrez PY - 2020/3/12/pubmed PY - 2020/3/12/medline KW - NEDA 3 KW - multiple sclerosis KW - new DMTs KW - old DMTs KW - pregnancy SP - 105 EP - 105 JF - Frontiers in neurology JO - Front Neurol VL - 11 N2 - Introduction: Trends of disease activity during pregnancy, the postpartum period, and until 24 months from the delivery in the era of new drugs for the treatment of relapsing-remitting multiple sclerosis (RRMS) need to be investigated. Methods: In this cross-sectional Italian multicenter study, women with RRMS were included; the disease-modifying treatment (DMT) at the time of conception included were: interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, fingolimod, and natalizumab. The main outcome of the study was to determine the rate of relapse occurrence during pregnancy and the postpartum period in all women grouped for each DMT. The secondary outcome was to determine the overall disease activity assessed by NEDA 3 (relapse, disability level, and radiological activity) at 24 months from the date of delivery. Results: Completed data were available for 81 pregnancies (in 74 women). Women on interferons and glatiramer had longer disease duration than women on dimethyl fumarate, fingolimod, and natalizumab (p < 0.05). Overall, we recorded 25 relapses during pregnancy (11 in 11 women) and the postpartum period (14 in 14 women). Natalizumab was the most commonly DMT in women (3) who experienced relapses during pregnancy. IFNs were the most commonly prescribed DMT in women (8) who experienced relapses during the postpartum period. At logistic regression analysis, specific treatment per se was not associated with relapse occurrence. No differences among the DMTs groups were recorded about NEDA 3 status at 24 months of follow-up. Conclusions: In our population, there was no difference in terms of relapses occurrence, disability status, and the overall disease activity during a follow up of 24 months. SN - 1664-2295 UR - https://www.unboundmedicine.com/medline/citation/32158424/Pregnancy_and_the_Postpartum_Period_in_Women_With_Relapsing-Remitting_Multiple_Sclerosis_Treated_With_Old_and_New_Disease-Modifying_Treatments:_A_Real-World_Multicenter_Experience L2 - https://doi.org/10.3389/fneur.2020.00105 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.